Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,909,572
  • Shares Outstanding, K 51,624
  • Annual Sales, $ 190,410 K
  • Annual Income, $ 20,890 K
  • EBIT $ 9 M
  • EBITDA $ 11 M
  • 60-Month Beta -2.80
  • Price/Sales 9.08
  • Price/Cash Flow 78.38
  • Price/Book 3.99

Options Overview Details

View History
  • Implied Volatility 87.61% (-2.85%)
  • Historical Volatility 67.66%
  • IV Percentile 85%
  • IV Rank 56.58%
  • IV High 124.05% on 10/20/25
  • IV Low 40.13% on 08/14/25
  • Expected Move (DTE 15) 6.12 (15.50%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 2,111
  • Volume Avg (30-Day) 2,419
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 50,140
  • Open Int (30-Day) 40,869
  • Expected Range 33.37 to 45.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.73
  • Number of Estimates 6
  • High Estimate $0.93
  • Low Estimate $0.62
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +176.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.43 +34.18%
on 03/27/26
41.10 -3.92%
on 03/10/26
+0.43 (+1.10%)
since 03/02/26
3-Month
29.43 +34.18%
on 03/27/26
50.88 -22.39%
on 01/08/26
-7.68 (-16.28%)
since 01/02/26
52-Week
29.43 +34.18%
on 03/27/26
90.32 -56.28%
on 07/09/25
-34.18 (-46.40%)
since 04/02/25

Most Recent Stories

More News
Soleno Therapeutics, Inc. Class Action Lawsuit: Investors Face May 5, 2026, Deadline

Did you buy SLNO common stock between March 26, 2025, and November 4, 202 5?

SLNO : 39.49 (+6.76%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SLNO

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO).   Such...

SLNO : 39.49 (+6.76%)
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , April 1, 2026 /PRNewswire/ --  The Law Offices of Frank R. Cruz announces that investors with losses related to Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: ...

SLNO : 39.49 (+6.76%)
Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman

SAN FRANCISCO , April 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno...

SLNO : 39.49 (+6.76%)
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug Safety

SLNO : 39.49 (+6.76%)
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , March 31, 2026 /PRNewswire/ --

SLNO : 39.49 (+6.76%)
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Soleno Therapeutics, Inc. (NASDAQ: SLNO).

SLNO : 39.49 (+6.76%)
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

SLNO Investors with Losses Encouraged to Contact Hagens Berman

SLNO : 39.49 (+6.76%)
SLNO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options

SLNO : 39.49 (+6.76%)
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ...

SLNO : 39.49 (+6.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 45.13
2nd Resistance Point 42.60
1st Resistance Point 41.05
Last Price 39.49
1st Support Level 36.97
2nd Support Level 34.44
3rd Support Level 32.89

See More

52-Week High 90.32
Fibonacci 61.8% 67.06
Fibonacci 50% 59.87
Fibonacci 38.2% 52.69
Last Price 39.49
52-Week Low 29.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.